Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBITDA (2016 - 2023)

Historic EBITDA for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $53.8 million.

  • RedHill Biopharma's EBITDA rose 35898.73% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$79.2 million, marking a year-over-year decrease of 84194.01%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 10380772528.95% down from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's EBITDA is $53.8 million, which was up 35898.73% from -$29.1 million recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's EBITDA registered a high of $53.8 million during Q2 2023, and its lowest value of -$139.6 million during Q4 2022.
  • For the 5-year period, RedHill Biopharma's EBITDA averaged around -$11.4 million, with its median value being $10.4 million (2019).
  • As far as peak fluctuations go, RedHill Biopharma's EBITDA plummeted by 47280.19% in 2022, and later skyrocketed by 35898.73% in 2023.
  • Over the past 5 years, RedHill Biopharma's EBITDA (Quarter) stood at -$72.9 million in 2019, then tumbled by 75.56% to -$128.0 million in 2020, then soared by 80.96% to -$24.4 million in 2021, then plummeted by 472.8% to -$139.6 million in 2022, then skyrocketed by 138.5% to $53.8 million in 2023.
  • Its EBITDA stands at $53.8 million for Q2 2023, versus -$29.1 million for Q1 2023 and -$139.6 million for Q4 2022.